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Abstract: Malignant peripheral nerve sheath tumor (MPNST) is a soft tissue sarcoma, 
which is difficult to distinguish from other spindle cell sarcomas. MPNST is hostile, 
with a high recurrence, and tends to metastasize hematogenously, especially to the 
lungs. A phase of the metastasis is a degradation of the extracellular matrix, where 
Matrix Metalloproteinase (MMP) plays an essential role in this process. Gelatinase-
type MMP, MMP-2 and MMP-9, can degrade basal membrane and fibrillar collagen to 
open the invasion pathway. MMP-2 can degrade more collagen and non-collagen 
extracellular matrix than MMP-9. Therefore, the study aimed to see the relationship 
between MMP-2 overexpression and histopathological malignancy grading and other 
clinical prognostic variables. The study was conducted by immunohistochemical 
staining of MMP-2 in 39 cases, consisting of 19 cases of low-grade MPNST and 20 
cases of high-grade MPNST. Subsequently, an analysis of the relationship between 
MMP-2 overexpression and the malignancy grading and clinical variables was 
performed, such as age, sex, and tumor size and location. MMP-2 overexpression was 
seen in 19 (95%) cases of high grade and three (15.8%) cases of low-grade MPNST (p 
0.000). The study also found a significant relationship between MMP-2 overexpression 
and histopathology grading, which may be helpful to define the prognosis. 
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Abstrak: Malignant peripheral nerve sheath tumor (MPNST) adalah sarkoma jaringan lunak 
yang sulit dibedakan dengan jenis sarkoma sel epitel spindel lainnya. MPNST bersifat agresif 
dengan angka rekurensi yang tinggi dan cenderung bermetastasis terutama ke paru. Salah satu 
tahap metastasis dengan cara mendegradasi matriks ekstraseluler dimana Matrix 
Metalloproteinase (MMP) berperan penting dalam proses ini. MMP tipe gelatinase yaitu MMP-
2 dan MMP-9 memiliki kemampuan dalam mendegradasi membran basal dan kolagen fibrillar 
sehingga dapat membuka jalur invasi. MMP-2 mampu mendegradasi lebih banyak matriks 
ekstraseluler kolagen dan non kolagen dibandingkan MMP-9. Penelitian bertujuan menilai 
hubungan antara peningkatan ekspresi MMP-2 dengan derajat keganasan histologik dan 
variabel prognostik klinis lainnya. Penelitian dilakukan dengan pulasan imunohistokimia 
MMP-2 pada 39 kasus yang terdiri atas 19 kasus MPNST derajat rendah dan 20 kasus 
MPNST derajat tinggi. Selanjutnya analisis hubungan antara peningkatan ekspresi MMP-2 
dengan derajat keganasan dan variabel klinis seperti usia, jenis kelamin, ukuran dan lokasi 
tumor. Peningkatan ekspresi MMP-2 ditemukan pada 19 (95%) kasus MPNST derajat tinggi 
dan 3 (15,8%) kasus MPNST derajat rendah (p 0,000). Penelitian ini menemukan hubungan 
yang kuat antara peningkatan ekspresi MMP-2 dengan derajat keganasan MPNST. 
Peningkatan ekspresi MMP-2 sejalan dengan peningkatan derajat histologik, sehingga dapat 
digunakan dalam menilai progresivitas MPNST. 
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Malignant Peripheral Nerve Sheath Tumor (MPNST) is an ectomesenchymal tumor that is difficult to 
diagnose because of its identical morphology to other spindle cell sarcoma.1 The diagnosis of soft tissue 
tumor refers to the grading system of the French Federation of Cancer Centre against Cancers (FNCLCC), 
while histological type alludes to WHO soft tissue and musculoskeletal. The prominent role in determining 
tumor grading is to measure the possibility of distant metastasis, which correlates with the patient’s 
prognosis.1,2 
MPNST has a poor prognosis and is one of the most aggressive sarcomas, with a high recurrence 
rate and a tendency to metastasize to the lungs.3 In this regard, Matrix Metalloproteinase (MMP) takes an 
important role in matrix degradation and contributes to tumor invasion and metastasis. Many types of MMP, 
namely gelatinase types such as MMP-2 and MMP-9, are essential for the development of malignant 
tumors.4,5 Gelatinase is the main enzyme to degrade the basal membrane and fibrillar collagen to pave the 
way for cell invasion.6-8 MMP-2 can degrade type I-IV collagen and extracellular matrix (ECM) non-collagen 
compared to MMP-9 that cannot degrade type I-III collagen and ECM non-collagen. In addition, metastasis of 
malignant cells produces a large amount of MMP-2 by stimulating the surrounding stromal cells to produce 
MMP-2. MMP-2 overexpression can be found in cell migration, invasion, and metastasis.9 
Moreover, MMP inhibitors can impede MMP activity, especially MMP-2 activity, in tumor growth and 
spread. One of the MMP inhibitors that can be used as a potential target of cancer therapy is batimastat. 
Batimastat is a synthetic MMP inhibitor that functions as an antineoplastic and antiangiogenic.9 Besides, MMP 
inhibitors can be a potential therapy in several pathological conditions, including inflammatory processes and 
cancer.10 
Research conducted by carrying out Matrix Metalloproteinase-2 for MPNST cases was first 
performed at the Anatomical Pathology Laboratory, Faculty of Medicine, University of Indonesia, Cipto 
Mangunkusumo Hospital Jakarta. It is expected that MMP-2 can be used as a prognostic factor for MPNST 
progression and provide hope for a new treatment method in cases where total resection is not possible by 
providing an additional therapy in the form of targeted therapy.10 Targeted therapy works by preventing 
extracellular matrix damage caused by MMP-2.11 Thus, this research assessed the differences in MMP-2 
expressions in low- and high-grade MPNST with tumor’s ability to metastasize and the patient’s prognosis. 
 
MATERIALS AND METHOD 
 
This research worked on a descriptive-analytical cross-sectional design and was approved by the 
Institutional Review Board. This study registered 39 cases, consisting of 19 cases of low-grade MPNST and 20 
cases of high-grade MPNST from our hospital from July 2007 to November 2014.  
For MMP-2 immunostaining, 4-mm-thick paraffin sections were cut and mounted on poly-L-lysine 
glass slides. The slides were deparaffinized in xylene and rehydrated with ethanol. Endogenous peroxidase 
was blocked using 95 ml of methanol plus 5 ml of 3% hydrogen peroxide solution. Heat-based antigen retrieval 
was carried out for ten min. Primary antibodies used were from Biocare Medical for MMP-2 (dilution 1:25). 
Slides were incubated for an hour with the primary antibodies, followed by staining with streptavidin-biotin 
peroxidase. Slides were then revealed in a diaminobenzidine solution for two min and stained with 
hematoxylin for five min.  
Further, a placenta tissue was used as a positive control for MMP-2. Meanwhile, negative controls 
were acquired by discarding the primary antibodies. A cut-off point of >25% moderate to strong cytoplasmic 
immunoreactivity on the tumor cells was explained as a positive MMP-2 overexpression. MMP-2 expression 
was then scored. After that, the correlation between MMP-2 expression and histopathology grading and 
other clinical variables, such as age, gender, and tumor size and location, were analyzed. The descriptive data 
were presented in the frequency table. Besides, categorical variables were compared using Chi-square, with 
the alternative of Fisher's exact test.  In this case, P<0.05 was considered statistically significant. Statistical 




The characteristics of 39 patients were summed up, as presented in Table 1, either overall or 
according to the histopathological grade. Thirty-nine samples consisted of low-grade (n=19) and high-grade 




of data distribution, the Shapiro-Wilk normality analysis was used. If the p-value is >0.05, the data distribution 
shows normal. 
Five patients (13%) had disease associated with NF-1 syndrome, and the other 34 patients (87%) had 
no association with NF-1 syndrome, with age ranging from 27 until 66 years old. There were two cases for 
males and three cases for females. Then, high-grade MPNST differentiation was reassessed, and found three 
cases of rhabdomyoblast differentiation (15%) of all cases (Fig 2C). In addition, lymph node removal was found 
in four cases, consisting of two low-grade cases and two high-grade cases of MPNST, and there was only one 
case of metastasis to the lymph nodes with high-grade malignancy (Fig 1A and Fig 2A).  







Gender Male 16 (84) 12 (60) 
 Female  3 (16) 8 (40) 
Age <40 years old 8 (42) 7 (35) 
 ≥ 40 years old 11 (58) 13 (65) 
Tumor site Extremity 
9 (47.4) 6 (30) 
 Head and neck 5 (26.3) 8 (40) 
 Trunk 5 (26.3) 6 (30) 
Size (cm)  11.53 + 6.8 12.6 + 5.6 
Margin status Negative 11 (58) 8 (40) 
 Positive 1 (5) 4 (20) 
 Biopsy 5 (26) 4 (20) 
 No data 2 (10) 4 (20) 
 
Moreover, there was an increased MMP-2 expression in twenty-two cases (56.4%) but not in 
seventeen cases (43.6%). At low-grade MPNST (Fig 1C), MMP-2 expression increased in three cases (15.8%) 
(Fig 1B), but it did not exist in the other 16 cases (84.2%) (Fig 1D). Meanwhile, at high-grade MPNST, there 
were 19 cases (95%) of increased MMP-2 expression, but it was absent in one case (5%). 
Furthermore, MMP-2 expression either in male or female patients neither indicated a significant 
difference (p 0.083) nor MMP-2 expression in patients aged over or under 40 years old (p 0.261). The same 
results were also obtained for MMP-2 expression in extremities, head, neck, and trunk, which did not indicate 
a significant difference. In addition, a statistical test comparing two unpaired groups, the Fisher test, was 
employed to measure MMP-2 expression for tumor location, and there was no significance (p 0.363). 
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Table 2. MMP-2 Expression Concerning the Histopathological Grade and Clinical Variables 
Characteristic 







MPNST Low grade (n=19) 3 (15.8) 16 (84.2) 0.000
a 
 High grade (n=20) 19 (95) 1 (5)  
Gender Male 14 (63.6) 15 (36.4) 0.083
a 
 Female 8 (88.2) 2 (11.8)  
Age <40 years old 7 (31.8) 8 (47.1) 0.261
a 
 ≥40 years old 15 (68.2) 9 (52.9)  
Tumor site Extremity 
8 (53.3) 7 (46.7) 0.363b 
 Head and neck 7 (53.8) 6 (46.2)  
 Trunk 7 (63.6) 4 (36.4)  
Size (cm) ≤ 5 cm 1 (33.3) 2 (66.7) 0.884
a 
 >5 cm 21 (58.3) 15 (41.7)  
Total  22 (56.4) 17 (43.6)  
a= unpaired categorical comparative test of Chi-Square 
b= unpaired categorical comparative test of Fisher 
 
Table 2 shows a significant difference between MMP-2 expression at low and high grades at p 0.000. 
The odds ratio value was 101, and it indicates that the high-grade patients had a possibility (odds) of 101 times 


























Figure 1. Low-grade MPNST (A, C) HE staining; (B) Focal MMP-2 protein; 


































Figure 2. (A) High-grade MPNST, HE staining; (B) Diffuse MMP-2 protein; (C) High-grade MPNST with rhabdomyoblast 




 In this study, the ratio of male and female patients was 2.5:1. This data is not in accordance with the 
literature, which stated that there was no gender preference for MPNST.12 However, in the sporadic MPNST 
cases (de novo), females were more slightly higher than males.13 Conversely, the gender ratio in this study is 
consistent with the study of Schmidt et al, of 35 MPNST cases, there were 27 males (77.1%) and eight females 
(22.9%). It also supports several other studies, which suggested no difference in prognosis between males 
and females.12 
 The age of patients ranged from 13-66 years, and the majority was in the age of 41-50 years old for 12 
cases (31%). This data is similar to the literature in which MPNST is usually found in the fourth decade.13-16 
Concerning this, children rarely suffer from MPNST; however, if there is historical radiation and the presence 
of NF1, it can also happen in children until young adults.6,12,17 
 The presence of a historical case of plexiform neurofibroma and NF-1 type is considered a precursor 
lesion of MPNST.18 In this study, we found five cases with NF-1, in which one case was found in low grade and 
the other four cases in high grade, sized more than 5 cm for all. Based on the literature, patients with a history 
of NF-1 have multiple neurofibromatoses, so that the transformation towards malignancy is difficult to 
identify clinically, and most are high-grade tumors and larger than 5 cm. The presence of NF-1 in patients also 
increases the risk of metastasis by 15 % compared to the inexistence of NF-1 by 9%.17 
 In addition, most cases were high-grade malignancies (53.5%). In this regard, Stucky obtained the same 
result, in which 61% of cases were high grades.19 Hence, it is crucial to determine the grade of soft tissue tumor 
because the high-grade tumor has a greater tendency to metastasize than the low-grade tumor, associated 
with poor prognosis.19-21 Likewise, a high-grade MPNST has a 1.8-fold risk of death and a 2-fold risk of 
metastasis compared with a low grade.22 
 We also found three cases (7%) with rhabdomyoblastic differentiation in high-grade MPNST.23 Based 
on the literature study, there are 15% MPNST differentiation cases, such as rhabdomyoblastic, epithelioid, 
glandular, osteogenic, and neuroendocrine components, but rhabdomyoblastic is the most common and well 
known as Malignant Triton Tumor (MTT). In the FNCLCC grading system, MTT is categorized as a high-grade 
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11p15 and the c-myc gene amplification, leading to acting more aggressive in MTT compared to classic 
MPNST.14 
 If a tumor is larger than 5 cm, it is increasingly prominent and painful, which should be considered 
sarcoma. In this study, 36 cases (95%) were larger than 5 cm. Meanwhile, three cases (16%) tumors were 
measured less than 5 cm and found in low-grade MPNST. Besides, all high-grade tumors (100%) were larger 
than 5 cm. The average size of tumors with low-grade malignancy was 11.53 cm, and high-grade malignancy 
was 12.6 cm. These results are slightly different from Grimer’s study, with the average sarcoma size was 10.7 
cm.25 
 According to Grimer, patients with tumors larger than 25 cm have a risk of death 8.5 times greater 
than patients with tumors less than 5 cm at first diagnosed. The larger the tumor size, the worse the 
prognosis because it is related to local recurrence and distant metastasis, thereby increasing the risk of death. 
19,22 
 Moreover, most of MPNST was located in extremities by 38%, followed by the head and neck by 33%, 
and in the trunk area by 29 %. It aligns with the reference, stating that 45% of MPNST are located in the 
extremities, 34% in the trunk, and 19% in the head and neck. 20 In the peripheral areas, extremities have a better 
survival rate than the central area, such as in the trunk, head, and neck, because the tumor in extremities can 
be detected earlier and are more convenient for resection.17,22 
 However, tumors in the trunk, head, and neck have a three-fold risk of local recurrence than those in 
the extremities. It is due to the difficulty of total resection due to its deep location and adjacent to the vital 
organs in the head and neck.22,26 In addition, tumors located in the retroperitoneum, thorax, head, and neck 
have a low survival rate (15%) since they tend to be slowly detected so that the tumor has reached a large size 
and is difficult to excise extensively.26 The risk of death increases 2.5-fold if it is located in the trunk and 
retroperitoneum. Some cases are also located in rare areas, such as in the prostate, external genitalia, and 
orbita. Based on the literature, MPNST can occur in all parts of the body containing peripheral nerves. 27 
 The data showed a significant difference between the increased MMP-2 expression with a 
histopathological grade of MPNST. MMP-2 expression increased in high grade than in low grade (p 0.000). 
This study supports the reference statement that high-grade tumors showed increased MMP-2 expression 
compared to low grades.28 Besides, two variables for this study, histopathology grading and MMP-2 
expression, were strongly related to the odds ratio 101, meaning that MPNST patients with high grades were 
101 times more likely to give positive results for MMP-2 expression compared to the low-grade patients. 
 Based on the literature, high-grade MPNST can metastasize because the MMP-2 protein supports 
tumor growth, invasion, and metastasis.26 Stucky et al. revealed a significant association between high-grade 
tumors and tumors larger than 5 cm with a risk of distant metastasis. 19 
 Meanwhile, there was no significant correlation between MMP-2 expression on female (p 0.083), age 
(p 0261), tumor size (p 0.363), and tumor location (p 0884). Similar results have been reported by Benassi et 
al., stating a non-significant relationship between MMP-2 expression with the clinical variables of gender, 
age, and tumor size and location.29  
 In this study, we also found four cases of lymph nodes removal and only one case of lymph node 
metastasis with high-grade malignancy. In this regard, hematogenous metastasis occurs in the lungs and 
bones by 65%, while local recurrence occurs in 54% of cases. 
 Furthermore, three low-grade MPNSTs showed positive results on MMP-2 staining. This result proves 
that tumors with low-grade malignancies also have the potential to metastasize, even a bit similar to the 
research conducted by Benassi et al. that there was one case of low-grade MPNST experiencing metastasis.29
 One protein that functions in the invasion and metastasis process is MMP-2, usually found in tumors 
with high-grade malignancies. It supports the results of our study, in which MMP-2 overexpression was found 
by 95% in high-grade MPNST. Thus, it can be concluded that the high-grade MPNST had a greater risk of 
metastasis than low grade. Therefore, identifying potential metastasis with MMP-2 staining is vital to see if 




Our study revealed that MMP-2 expression was greater in high-grade MPNST than in low grade, 
correlated with histopathology grading, but did not correlate with clinical variables, such as gender, age, and 
tumor size and location. MMP-2 overexpression can be used as a prognostic factor in MPNST development. 
In addition, MMP-2 expression should be assessed in high-grade MPNST cases to predict metastasis; then, 
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